论文部分内容阅读
目的探讨朗格汉斯组织细胞增生症患者的预后情况及影响预后的因素。方法回顾性分析1996年9月至2014年5月郑州大学附属肿瘤医院收治的111例朗格汉斯组织细胞增多症患者的临床和随访资料,分析患者的复发情况,对可能影响患者无事件生存时间(EFS)和总生存时间(OS)的因素进行单因素分析。结果多部位骨质受累和多系统受累患者的复发率分别高于非多部位骨质受累和单系统受累的患者(P<0.05)。单因素分析显示,发病年龄≤2岁、多部位骨质受累、多系统受累、有危险器官受累、初始治疗无效的患者无事件生存率和总生存率均显著降低,应用化疗患者的无事件生存率和总生存率均显著升高(P<0.05)。结论发病年龄≤2岁、多部位骨质受累、有危险器官受累及初始治疗后疗效差是影响患者预后的重要因素。
Objective To investigate the prognosis of patients with Langerhans histiocytosis and its prognostic factors. Methods The clinical and follow-up data of 111 cases of Langerhans histiocytosis admitted to Cancer Hospital Affiliated to Zhengzhou University from September 1996 to May 2014 were analyzed retrospectively to analyze the recurrence of patients and the possible impact on the patients’ event-free survival Time (EFS) and total survival time (OS) were analyzed by univariate analysis. Results The recurrence rates of patients with multi-site bone involvement and multi-system involvement were significantly higher than those without multi-site bone involvement and single-system involvement (P <0.05). Univariate analysis showed that the incidence of event-free survival and overall survival were significantly decreased in patients with age less than 2 years, multi-site bone involvement, multiple system involvement, dangerous organ involvement, initial treatment failure, and event-free survival in patients undergoing chemotherapy Rate and overall survival were significantly increased (P <0.05). Conclusion The age of onset ≤ 2 years old, multi-site bone involvement, risk organ involvement and poor efficacy after initial treatment is an important factor affecting the prognosis of patients.